Safety management of targeted-immunotherapy combination for renal cell carcinoma
10.3969/j.issn.1009-8291.2025.11.001
- VernacularTitle:肾癌靶免联合药物安全性管理
- Author:
Hailiang ZHANG
1
;
Dingwei YE
1
;
Anwaier AIHETAIMUJIANG
1
Author Information
1. 复旦大学附属肿瘤医院泌尿外科,上海市泌尿生殖系统肿瘤研究所,复旦大学上海医学院肿瘤学系,上海 200032
- Publication Type:Journal Article
- Keywords:
renal cell carcinoma;
targeted therapy;
immunotherapy;
adverse effect;
safety management
- From:
Journal of Modern Urology
2025;30(11):911-917
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,the combined application of targeted-immunotherapy has become a recommended treatment option for advanced renal cell carcinoma in various guidelines.However,although this strategy has significant therapeutic effects and survival advantages,it is associated with a variety of adverse reactions that cannot be ignored.Therefore,how to effectively manage adverse reactions and ensure the treatment safety has become one of the core issues.This article systematically reviews the adverse effects and management strategies,discusses the early identification of adverse reactions,monitoring methods,the design of individualized treatment plans and future development,aiming to provide practical safety management guidance and explore the direction of future development.
